These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 534183)
1. [Nycterohemeral variations of growth hormone and prolactin in 6 Parkinson's sufferers treated with bromocriptine (author's transl)]. Passouant P; Besset A; Descomps B; Bonardet A; Billiard M; Nègre C Nouv Presse Med; 1979 Oct; 8(40):3237-42. PubMed ID: 534183 [TBL] [Abstract][Full Text] [Related]
2. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease. Bell RD; Carruth A; Rosenberg RN; Boyar RM J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469 [TBL] [Abstract][Full Text] [Related]
3. [Sleep-waking cycle and the nyctohemeral secretion of prolactin and somatotropin in Parkinson patients. Effect of bromocriptine]. Passouant P; Besset A Bull Acad Natl Med; 1980 Feb; 164(2):134-8. PubMed ID: 7004582 [No Abstract] [Full Text] [Related]
4. Effect of ergot alkaloids on growth hormone and prolactin secretion in humans. Silvestrini F; Liuzzi A; Chiodini PG Pharmacology; 1978; 16 Suppl 1():78-87. PubMed ID: 643905 [TBL] [Abstract][Full Text] [Related]
5. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response. Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625 [TBL] [Abstract][Full Text] [Related]
6. The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. Lamberts SW; de Quijada M; Klijn JG J Endocrinol Invest; 1980; 3(4):343-7. PubMed ID: 7204884 [TBL] [Abstract][Full Text] [Related]
7. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021 [TBL] [Abstract][Full Text] [Related]
8. Circadian rhythmicity of prolactin secretion in elderly subjects: changes during bromocriptine treatment. Polleri A; Masturzo P; Murialdo G; Agnoli A J Endocrinol Invest; 1981; 4(3):317-21. PubMed ID: 7320436 [TBL] [Abstract][Full Text] [Related]
9. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. Ishibashi M; Yamaji T J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273 [TBL] [Abstract][Full Text] [Related]
10. Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine. Hyyppä MT; Långvik VA; Rinne UK J Neural Transm; 1978; 42(2):151-7. PubMed ID: 650205 [TBL] [Abstract][Full Text] [Related]
11. Effects of the short-acting benzodiazepine triazolam, taken at bedtime, on circadian and sleep-related hormonal profiles in normal men. Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Szyper M; Caufriez A; Bosson D; L'Hermite M; Robyn C; Turek FW; Van Cauter E Sleep; 1990 Jun; 13(3):232-44. PubMed ID: 2356395 [TBL] [Abstract][Full Text] [Related]
12. [Bromocryptin effect on growth hormone and prolactin secretion after administration of thyrotropin-releasing hormone in patients with primary hypothyroidism and acromegaly (author's transl)]. Felt V; Nedvídková J; Krejcík L; Hainer V Cas Lek Cesk; 1977 May; 116(19):591-4. PubMed ID: 406999 [No Abstract] [Full Text] [Related]
13. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep. Clarenbach P; Del Pozo E; Brownell J; Heredia E; Spiegel R; Cramer H Brain Res; 1980 Dec; 202(2):357-63. PubMed ID: 7437907 [TBL] [Abstract][Full Text] [Related]
14. Induction of growth hormone and prolactin secretion by luteinizing hormone-releasing hormone and its blockade by bromoergocriptine in acromegalic patients. Ishibashi M; Yamaji T; Kosaka K J Clin Endocrinol Metab; 1978 Aug; 47(2):418-21. PubMed ID: 400720 [TBL] [Abstract][Full Text] [Related]
15. Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. Vance ML; Kaiser DL; Frohman LA; Rivier J; Vale WW; Thorner MO J Clin Endocrinol Metab; 1987 Jun; 64(6):1136-41. PubMed ID: 3553220 [TBL] [Abstract][Full Text] [Related]
16. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Ishibashi M; Yamaji T J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426 [TBL] [Abstract][Full Text] [Related]
17. Abnormal control of growth hormone secretion by opiate systems in acromegalic patients: a study with naloxone and 2-Br-alpha-ergocryptine (CB 154). Agnati LF; Benfenati F; Frank G; Capelli M; Bernardi P; Calza L Med Biol; 1981 Feb; 59(1):58-63. PubMed ID: 7266088 [TBL] [Abstract][Full Text] [Related]
18. Diurnal secretion profiles of growth hormone, thyrotrophin and prolactin in Parkinson's disease. Aziz NA; Pijl H; Frölich M; Roelfsema F; Roos RA J Neuroendocrinol; 2011 Jun; 23(6):519-24. PubMed ID: 21466597 [TBL] [Abstract][Full Text] [Related]
19. Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson's disease and Huntington's chorea. Murri L; Iudice A; Muratorio A; Polleri A; Barreca T; Murialdo G Eur Neurol; 1980; 19(3):198-206. PubMed ID: 6446454 [TBL] [Abstract][Full Text] [Related]